Literature DB >> 2174668

Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking.

C Grose1.   

Abstract

This article reviews major developments concerning the VZV glycoproteins. Very little was published about these viral products prior to the early 1980s. VZV is now known to encode five glycoproteins that have been designated gpI through gpV. The viral glycoproteins are present within the envelope of the complete virion; in addition, they are inserted in the plasma membrane of the infected cell. Studies of the assembly and processing of three of the VZV glycoproteins have demonstrated that they may contain both N-linked and O-linked glycans, some of which are also sulfated and sialated. A heretofore unappreciated modification of VZV gpI is phosphorylation. The glycoprotein is modified on its serine and threonine residues by at least two cellular protein kinases--casein kinases I and II. Finally, aspects of viral glycoprotein trafficking have been analyzed in VZV-infected cells. The pathway progresses from the trans-Golgi region via cytoplasmic vacuoles to the outer cellular membrane. The virus may acquire part of its glycoprotein-laden envelope from the cytoplasmic vacuoles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174668     DOI: 10.1146/annurev.mi.44.100190.000423

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  49 in total

1.  Trafficking of varicella-zoster virus glycoprotein gI: T(338)-dependent retention in the trans-Golgi network, secretion, and mannose 6-phosphate-inhibitable uptake of the ectodomain.

Authors:  Z H Wang; M D Gershon; O Lungu; Z Zhu; A A Gershon
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Role of PACS-1 in trafficking of human cytomegalovirus glycoprotein B and virus production.

Authors:  Colin M Crump; Chien-Hui Hung; Laurel Thomas; Lei Wan; Gary Thomas
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Autophagosome formation during varicella-zoster virus infection following endoplasmic reticulum stress and the unfolded protein response.

Authors:  John E Carpenter; Wallen Jackson; Luca Benetti; Charles Grose
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 5.  Viral infection and human disease--insights from minimotifs.

Authors:  Krishna Kadaveru; Jay Vyas; Martin R Schiller
Journal:  Front Biosci       Date:  2008-05-01

6.  B-cell epitopes of varicella-zoster virus glycoprotein II.

Authors:  A Kjartansdóttir; E Lycke; S R Norrby
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis.

Authors:  Stefan L Oliver; Jennifer J Brady; Marvin H Sommer; Mike Reichelt; Phillip Sung; Helen M Blau; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-15       Impact factor: 11.205

8.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

9.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

10.  Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex).

Authors:  Z Yao; C Grose
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.